Literature DB >> 10545016

Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats.

N Onier1, S Hilpert, L Arnould, V Saint-Giorgio, J G Davies, J F Jeannin, J F Jeannin.   

Abstract

The antitumoral effect of the new lipid A OM 174 was investigated in a model of colon cancer in rats. Peritoneal carcinomatosis were induced in BDIX rats by intraperitoneal injection of syngeneic PROb cancer cells. The treatment started 2 weeks later, when rats had macroscopic peritoneal nodules. An antitumoral effect was first obtained with OM 174 intraperitoneally injected, then an intravenous treatment was developed. When injected 15 times intravenously, at the dose of 1 mg/kg, 2 days apart, OM 174 induced the complete regression of tumors and hemorrhagic ascitis in 90% of the tumor-bearing rats, whereas all the untreated rats died of their tumors. To our knowledge, this treatment is the most effective ever applied to macroscopic tumors. Furthermore, the treatment induced the immunization of rats since the reinjection of PROb tumor cells in OM 174-cured rats did not cause the formation of new tumors while injection of another syngenic colon tumor cells did. Only in treated rats tumors were infiltrated with lymphocytes, macrophages and fibroblasts. The treatment did not increase necrosis but generated apoptotic areas. OM 174 was not directly toxic for tumor cells, and thus the observed effect involved the host-mediated antitumor reaction. Therefore we hypothesize that OM 174 therapy induces tumor cell apoptosis, stimulates the phagocytosis of apoptotic bodies and then activates immune system by antigen presentation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545016     DOI: 10.1023/a:1006663017149

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  26 in total

1.  Endotoxic properties of chemically synthesized lipid A part structures. Comparison of synthetic lipid A precursor and synthetic analogues with biosynthetic lipid A precursor and free lipid A.

Authors:  C Galanos; V Lehmann; O Lüderitz; E T Rietschel; O Westphal; H Brade; L Brade; M A Freudenberg; T Hansen-Hagge; T Lüderitz
Journal:  Eur J Biochem       Date:  1984-04-16

2.  Biological response to intravenously administered endotoxin in patients with advanced cancer.

Authors:  R Engelhardt; A Mackensen; C Galanos; R Andreesen
Journal:  J Biol Response Mod       Date:  1990-10

3.  Antitumor and antimicrobial activities of lipid A-subunit analogue GLA-27.

Authors:  M Nakatsuka; Y Kumazawa; S Ikeda; A Yamamoto; C Nishimura; J Y Homma; M Kiso; A Hasegawa
Journal:  J Clin Lab Immunol       Date:  1988-05

4.  Correlation between the capacity to activate macrophages in vitro and the antitumor activity in vivo of lipopolysaccharides from different bacterial species.

Authors:  C Blondiau; P Lagadec; P Lejeune; N Onier; J M Cavaillon; J F Jeannin
Journal:  Immunobiology       Date:  1994-04       Impact factor: 3.144

5.  Bcl-2-mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors.

Authors:  B Bonnotte; N Favre; M Moutet; A Fromentin; E Solary; M Martin; F Martin
Journal:  J Immunol       Date:  1998-08-01       Impact factor: 5.422

6.  Treatment with endotoxins of peritoneal carcinomatosis induced by colon tumor cells in the rat.

Authors:  P Lagadec; J F Jeannin; D Reisser; H Pelletier; O Olsson
Journal:  Invasion Metastasis       Date:  1987

7.  Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium.

Authors:  N Qureshi; K Takayama; E Ribi
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

8.  Effect of combined administration of a synthetic low-toxicity lipid A derivative, DT-5461a, and indomethacin in various experimental tumor models of colon 26 carcinoma in mice.

Authors:  T Jimbo; T Akimoto; A Tohgo
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

9.  Regression induced by lentinan, of peritoneal carcinomatoses in a model of colon cancer in rat.

Authors:  J F Jeannin; P Lagadec; H Pelletier; D Reisser; N O Olsson; G Chihara; F Martin
Journal:  Int J Immunopharmacol       Date:  1988

10.  Antitumor effect of DT-5461a, a synthetic low-toxicity lipid A analog, involves endogenous tumor necrosis factor induction subsequent to macrophage activation.

Authors:  T Akimoto; E Kumazawa; T Jimbo; N Joto; A Tohgo
Journal:  Int J Immunopharmacol       Date:  1994-11
View more
  13 in total

Review 1.  Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.

Authors:  Pierpaolo Correale; Maria Grazia Cusi; Lucia Micheli; Cristina Nencini; Maria Teresa Del Vecchio; Francesco Torino; Angelo Aquino; Enzo Bonmassar; Guido Francini; Giorgio Giorgi
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

2.  TLR4/IFNγ pathways induce tumor regression via NOS II-dependent NO and ROS production in murine breast cancer models.

Authors:  Myriam Lamrani; Nejia Sassi; Catherine Paul; Nadhir Yousfi; Jean-Luc Boucher; Nolwenn Gauthier; Jérôme Labbé; Cédric Seignez; Cindy Racoeur; Anne Athias; Romain Guerreiro; Catherine Vergely; Luc Rochette; Ali Bettaieb; Jean-François Jeannin
Journal:  Oncoimmunology       Date:  2015-12-29       Impact factor: 8.110

Review 3.  Big opportunities for small molecules in immuno-oncology.

Authors:  Jerry L Adams; James Smothers; Roopa Srinivasan; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2015-07-31       Impact factor: 84.694

4.  Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.

Authors:  Nicolas Isambert; Pierre Fumoleau; Catherine Paul; Christophe Ferrand; Sylvie Zanetta; Jacques Bauer; Kevin Ragot; Gérard Lizard; Jean-François Jeannin; Marc Bardou
Journal:  BMC Cancer       Date:  2013-04-02       Impact factor: 4.430

5.  Gene expression disorders of innate antibacterial signaling pathway in pancreatic cancer patients: implications for leukocyte dysfunction and tumor progression.

Authors:  Robert Słotwiński; Aleksandra Dąbrowska; Gustaw Lech; Maciej Słodkowski; Sylwia M Słotwińska
Journal:  Cent Eur J Immunol       Date:  2014-12-15       Impact factor: 2.085

Review 6.  Toll-like receptor-4 modulation for cancer immunotherapy.

Authors:  Shanjana Awasthi
Journal:  Front Immunol       Date:  2014-07-25       Impact factor: 7.561

7.  Senescence of tumor cells induced by oxaliplatin increases the efficiency of a lipid A immunotherapy via the recruitment of neutrophils.

Authors:  Cédric Seignez; Amandine Martin; Claire-Emmanuelle Rollet; Cindy Racoeur; Alessandra Scagliarini; Jean-François Jeannin; Ali Bettaieb; Catherine Paul
Journal:  Oncotarget       Date:  2014-11-30

Review 8.  Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer.

Authors:  Robert Słotwiński; Sylwia Małgorzata Słotwińska
Journal:  Cent Eur J Immunol       Date:  2017-01-24       Impact factor: 2.085

9.  Tumor-derived granzyme B-expressing neutrophils acquire antitumor potential after lipid A treatment.

Authors:  Amandine Martin; Cédric Seignez; Cindy Racoeur; Nicolas Isambert; Nesrine Mabrouk; Alessandra Scagliarini; Sylvie Reveneau; Laurent Arnould; Ali Bettaieb; Jean-François Jeannin; Catherine Paul
Journal:  Oncotarget       Date:  2018-06-19

Review 10.  A Rosetta Stone for Breast Cancer: Prognostic Value and Dynamic Regulation of Neutrophil in Tumor Microenvironment.

Authors:  Wei Zhang; Yimin Shen; Huanhuan Huang; Sheng Pan; Jingxin Jiang; Wuzhen Chen; Ting Zhang; Chao Zhang; Chao Ni
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.